Vice Chair for Translational Research, Department of Radiation Oncology; Professor of Radiation Oncology, Urology, and Medicine. Dr. Feng is a radiation oncology leader in translational research. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive prostate cancer, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers. Dr. Feng serves on the National Cancer Institute Genitourinary Cancer Steering Committee, which oversees and evaluates clinical trials proposed by all national clinical trials cooperative groups. He also serves as Chair of the Biology Scientific Track for the American Society of Radiation Oncology, and as Chair of the Genitourinary Translational Research Program for the RTOG/NRG national cooperative group.
In addition, Dr. Feng is a successful entrepreneur. He recently raised $75M of institutional investment for an artificial intelligence start-up company he co-founded. This was following a $15M raise for another firm he co-founded involved with cancer therapeutics.

Links

GoogleScholar
University of California, San Francisco

A Professor of Computing Science at Simon Fraser University in Burnaby, British Columbia. He received a Diplom (M.Sc.) in Computer Science from University of Dortmund, Germany, in 1984 and a Ph.D. in Computer Science from ETH Zurich, Switzerland, in 1990. Dr. Ester is a co-director of the Databases and Data Mining Laboratory and member of the Omics Data Science Research Cluster. His research interests are in Data Mining and Machine Learning, in particular causal pattern discovery, transfer learning, network analysis, and recommender systems. Much of his research is driven by bio-medical applications such as patient stratification and drug response prediction. His methods are typically based on Probabilistic Graphical Models and Deep Neural Networks.
Dr. Ester is a world leader in Machine Learning and a strong supporter of using Machine Learning in biotechnology.

Links

GoogleScholar

Wikipedia

Clinical Professor, University of British Columbia and gynecologic oncologist/clinician scientist Dr. Carey runs a translational cancer research program studying preclinical drug evaluation and predictive biomarker discovery in rare and aggressive gynecological cancers. Dr. Carey is co-chair of the gynecologic disease site group for the Canadian Cancer Trials Group (CCTG), and a member of the Gynecological Cancer Intergroup, an international clinical trials cooperative. Dr. Carey is a member of the Gynecologic Cancer Steering Committee providing oversight for the review and approval of clinical trials for the National Clinical Trials Network under the auspices of the National Cancer Institute.

Links
ResearchGate

Head of Molecular Pathology & Cell Imaging Core Facility, and a Senior Research Scientist at the Vancouver Prostate Centre and an Associate Professor, Department of Urologic Sciences, University of British Columbia. He is a molecular biologist specialized in cancer tumor-associated stress signaling pathways and tumor targeting systems. Dr. Daugaard is also a decorated entrepreneur founding two highly successful companies as an outcome of his research.

Links
GoogleScholar